WaveMan
WaveMan · Company
VNDA · Vanda Pharmaceuticals Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

VNDA Vanda Pharmaceuticals (VNDA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001347178
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
96
13F, latest reported quarter

Vanda Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Vanda Pharmaceuticals Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Williams Timothy
SVP & General Counsel
SELL
2026-03-04 SECtraded 2026-03-02
42,434
$350.9K
-49.6%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Mar 5, 2024.
  • The trade is 11.2% of the 377,450 shares held after it.
  • 5 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & General Counsel Williams Timothy sold about $350.9K of VNDA on Mar 2, 2026, the largest insider sale at the company since 2022; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
Moran Kevin Patrick
SVP, CFO & Treasurer
SELL
2026-03-04 SECtraded 2026-03-02
42,442
$351.0K
-49.6%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (1 buy, 13 sales), the last on Feb 21, 2025.
  • The trade is 10.3% of the 411,380 shares held after it.
  • 5 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, CFO & Treasurer Moran Kevin Patrick sold about $351.0K of VNDA on Mar 2, 2026, the largest insider sale at the company since 2022; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
Wijkstrom Joakim
SVP, Chief Marketing Officer
SELL
2026-03-04 SECtraded 2026-03-02
30,800
$254.7K
-49.6%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 5, 2024.
  • The trade is 9.2% of the 333,469 shares held after it.
  • 5 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Marketing Officer Wijkstrom Joakim sold about $254.7K of VNDA on Mar 2, 2026, the largest insider sale at the company since 2022; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
Polymeropoulos Mihael Hristos
President and CEO
SELL
2026-03-04 SECtraded 2026-03-02
156,235
$1.3M
-49.6%
Context
  • 24 earlier Form 4 trades (code P or S) here by this insider (14 buys, 10 sales), the last on Aug 7, 2025.
  • -7.9% median (-4.3% mean) 90-day return after 10 previous buys.
  • The trade is 5.8% of the 2,704,496 shares held after it.
  • 5 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Polymeropoulos Mihael Hristos sold about $1.3M of VNDA on Mar 2, 2026, the largest insider sale at the company on our record; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
Birznieks Gunther
SVP, Business Development
SELL
2026-03-04 SECtraded 2026-03-02
42,431
$350.9K
-49.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 5, 2024.
  • The trade is 8.6% of the 494,197 shares held after it.
  • 5 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Business Development Birznieks Gunther sold about $350.9K of VNDA on Mar 2, 2026, the largest insider sale at the company since 2022; 5 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
77 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 72 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
96 funds bought in last quarter
more than 66% of Pharma & Biotech
Revenue
+8.7% year over year
more than 58% of Pharma & Biotech
Margin
-102.0% net margin
below 58% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.8% of the float short (float per yahoo 2026-10-27) · 8.3 days to cover · settled 2026-10-15
more than 83% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch VNDA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-27.3%12M
-28%+6%+40%+74%2025-102025-122026-022026-042026-062026-082026-10 2026-03-02 · Polymeropoulos Mihael Hristos sold $1.3M2026-03-02 · Moran Kevin Patrick sold $351.0K2026-03-02 · Williams Timothy sold $350.9K2026-03-02 · Birznieks Gunther sold $350.9K2026-03-02 · Wijkstrom Joakim sold $254.7K2026-02-23 · Honore Tage sold $240.9K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VNDA: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
7,653,737 sh
$46.8M
STATE STREET CORP
3,516,405 sh
$21.5M
AQR CAPITAL MANAGEMENT LLC
3,497,695 sh
$21.4M
RENAISSANCE TECHNOLOGIES LLC
3,441,361 sh
$21.1M
VANGUARD CAPITAL MANAGEMENT LLC
2,524,040 sh
$15.4M

Congress trades in VNDA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VNDA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

VNDA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND
$220.6K position · as of 2026-06-30
0.7%
Horizon Kinetics Medical ETF
$138.6K position · as of 2026-06-30
0.7%
NVIT Small Cap Value Fund
$717.0K position · as of 2026-06-30
0.3%
Invesco NASDAQ Future Gen 200 ETF
$55.6K position · as of 2026-05-31
0.3%
GMO U.S. Small Cap Value Fund
$130.1K position · as of 2026-05-31
0.3%
Federated Hermes MDT Small Cap Core Fund
$5.5M position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
55 registered trials, 16 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
7
Phase 1
1 active
18
Phase 2
3 active
24
Phase 3
9 active
1
Phase 4
1 active
3
Not applicable
1 active
2
Multi-phase
1 active
What changed recently
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
2026-10-20 · Completion moved 2025-12 → 2026-03-30
Phase 3
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
2026-10-20 · Recruiting → Completed
Phase 3
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (
2026-10-10 · Completion moved 2026-09 → 2026-09-04
Phase 3
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (
2026-10-10 · Active Not Recruiting → Completed
Phase 3
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
2026-10-01 · Completion moved 2026-03-31 → 2028-12-31
Phase 4
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr. Mihael H. Polymeropoulos
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.9M
$7.6M
$1.4M
-33%
+20%
2024
$3.9M
$4.3M
$1.3M
-64%
-9%
2023
$3.7M
$1.8M
$1.4M
-68%
-8%
2022
$4.3M
$859.6K
$1.5M
-44%
-11%
2021
$6.2M
$5.6M
$2.0M
+19%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 96 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

VNDA financials

Revenue growth
+8.7%
XBRL, annual
Net margin
-102.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$215.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-127.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$143.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-77.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-53.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-49.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-59.3%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$216.1M$198.8M$192.6M$254.4M
Operating income-$151.2M-$40.7M-$14.0M$6.3M
Net income-$220.5M-$18.9M$2.5M$6.3M
EPS (diluted)-3.74-0.330.040.11
Operating cash flow-$109.4M-$15.8M$12.8M$32.0M
Cash$84.9M$102.3M$135.8M$135.0M
SEC XBRL, fiscal years, as known on 2026-10-28

VNDA Stock Sonar score 4/7 axes

Find similar shapesCompare

VNDA ranks highest on institutional and government (66th percentile) and growth (58th), and lowest on risk and compliance (31st), among Pharma & Biotech peers.

Profitability
45
Inputs
  • Return on equity-77.8% · 40 pct, sector of 545
  • Return on assets-53.0% · 43 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-49.4% · 52 pct, sector of 576
Growth
58
Inputs
  • Revenue growth, YoY+8.7% · 58 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
66
Inputs
  • Funds adding, latest quarter96 · 66 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
31
Inputs
  • Short interest, % of float+17.8% · 19 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+12.2% · 42 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies